Curanex Pharmaceuticals Inc Operating Lease, Expense
Curanex Pharmaceuticals Inc (CURX) reported Operating Lease, Expense of $40.49 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-14
- Curanex Pharmaceuticals Inc operating lease, expense for the quarter ending 2026-06-30 was $40.49K, a 132.67% increase year-over-year.
- Curanex Pharmaceuticals Inc operating lease, expense for the quarter ending 2026-03-31 was $39.44K, a 126.63% increase year-over-year.
- Curanex Pharmaceuticals Inc operating lease, expense for the quarter ending 2025-12-31 was $35.83K.
- Curanex Pharmaceuticals Inc operating lease, expense for the quarter ending 2025-09-30 was $17.40K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.49K 10-Q · filed 2026-08-14 | $79.94K 10-Q · filed 2026-08-14 | $115.77K derived: sum of 3 quarters · filed 2026-08-14 | $133.17K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $39.44K 10-Q · filed 2026-05-14 | $75.27K derived: sum of 2 quarters · filed 2026-05-14 | $92.68K derived: sum of 3 quarters · filed 2026-05-14 | $110.08K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $35.83K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-05-14 | $53.23K derived: sum of 2 quarters · filed 2026-05-14 | $70.64K derived: sum of 3 quarters · filed 2026-08-14 | $88.04K 10-Q · filed 2026-05-14 |
| 2025-09-30 | $17.40K 10-Q · filed 2025-11-17 | $34.81K derived: sum of 2 quarters · filed 2026-08-14 | $52.21K 10-Q · filed 2025-11-17 | |
| 2025-06-30 | $17.40K 10-Q · filed 2026-08-14 | $34.81K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $17.40K 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |